TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
34.78
+0.76 (2.23%)
At close: Oct 31, 2025, 4:00 PM EDT
35.30
+0.52 (1.50%)
After-hours: Oct 31, 2025, 7:58 PM EDT
TG Therapeutics Employees
TG Therapeutics had 338 employees as of December 31, 2024. The number of employees increased by 74 or 28.03% compared to the previous year.
Employees
338
Change (1Y)
74
Growth (1Y)
28.03%
Revenue / Employee
$1,343,399
Profits / Employee
$178,870
Market Cap
5.07B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 338 | 74 | 28.03% |
| Dec 31, 2023 | 264 | 38 | 16.81% |
| Dec 31, 2022 | 226 | -60 | -20.98% |
| Dec 31, 2021 | 286 | 14 | 5.15% |
| Dec 31, 2020 | 272 | 138 | 102.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TGTX News
- 1 day ago - TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 4 days ago - TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI - GlobeNewsWire
- 5 weeks ago - New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment - GlobeNewsWire
- 7 weeks ago - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting - GlobeNewsWire
- 7 weeks ago - TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment - GlobeNewsWire
- 2 months ago - TG Therapeutics, Inc. (TGTX) Presents at Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program - GlobeNewsWire